Critical Review: TriSalus Life Sciences (TLSI) and Its Peers

TriSalus Life Sciences (NASDAQ:TLSI) is one of 237 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its peers? We will compare TriSalus Life Sciences to related businesses based on the strength of its dividends, profitability, risk, analyst recommendations, earnings, institutional ownership and valuation.

Institutional and Insider Ownership

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 32.8% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 15.2% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares TriSalus Life Sciences and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-219.71%	N/A	-192.99%
TriSalus Life Sciences Competitors	-566.49%	-179.54%	-27.74%

Risk & Volatility

TriSalus Life Sciences has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences’ peers have a beta of 0.47, suggesting that their average stock price is 53% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for TriSalus Life Sciences and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	0	0	6	2	3.25
TriSalus Life Sciences Competitors	1899	4886	9159	268	2.48

TriSalus Life Sciences currently has a consensus price target of $12.08, indicating a potential upside of 207.46%. As a group, “Surgical & medical instruments” companies have a potential upside of 19.36%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, equities analysts plainly believe TriSalus Life Sciences is more favorable than its peers.

Earnings and Valuation

This table compares TriSalus Life Sciences and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TriSalus Life Sciences	$24.74 million	-$59.04 million	-1.58
TriSalus Life Sciences Competitors	$1.03 billion	$10.50 million	-20.40

TriSalus Life Sciences’ peers have higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

TriSalus Life Sciences beats its peers on 9 of the 13 factors compared.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.